Copyright
©©The Author(s) 2022.
World J Stem Cells. Jan 26, 2022; 14(1): 76-91
Published online Jan 26, 2022. doi: 10.4252/wjsc.v14.i1.76
Published online Jan 26, 2022. doi: 10.4252/wjsc.v14.i1.76
Cell-surface markers | Function | Physiological significance | Involved signaling pathways | Therapeutic targets or inhibitor | Prognostic marker of GC | Ref. | ||||
Tumorigenicity/GCSC generation | Spheroid formation | Chemo-resistance | Radio-resistance | EMT/metastasis | ||||||
CD44 | Hyaluronic acid receptor | ● | ● | ● | ND | ● | Wnt/β-catenin pathway | CD44 | ● | [21-24] |
CD44H | Hyaluronic acid receptor | ● | ● | ● | ND | ND | Wnt/β-catenin pathway | CD44 | ● | [25] |
CD44v | Hyaluronic acid receptor | ● | ● | ND | ND | ● | Glutathione metabolism | Glutathione metabolismsulfasalazine (SSZ) | ● | [25-28] |
CD44+CD24 | Cell adhesion molecule | ● | ● | ● | ND | ND | Notch pathway | CD44+CD24 | ● | [24,29] |
CD44+CD54 | Cell adhesion molecule | ● | ● | ● | ND | ND | Wnt/β-catenin pathway | CD44+CD54 | ND | [22,24,30] |
CD44+EpCAM | Cell adhesion molecule/epithelial cell adhesion molecule | ● | ● | ● | ND | ND | Wnt/β-catenin pathway | ND | ND | [24,31] |
CD71- | Transferrin receptor | ● | ND | ND | ND | ● | uptake of transferrin/iron | CD71 | ● | [32] |
CD90 | Immunoglobulin superfamily/Thy-1 cell-surface antigen | ● | ● | ND | ND | ● | Notch pathway | CD90trastuzumab | ND | [24,33] |
CD133 | Pentaspan transmembrane glycoprotein | ● | ● | ND | ND | ND | MAPK/ERK pathway | CD133 | ● | [24] |
Lgr5 | Leucine-rich repeat-containing G-protein coupled receptor 5 | ● | ND | ● | ND | ● | Notch-mTOR pathway | Notch-mTOR pathwayMiR-132Anti-Lgr5 | ● | [34-38] |
ALDH1 | Aldehyde dehydrogenase 1 | ● | ● | ● | ● | ● | Wnt/β-catenin pathway | TGF- | ● | [39] |
CD44+CD166+ALDH | Activated leukocyte cell adhesion molecule (ALCAM) | ● | ● | ● | ND | ● | Wnt/β-catenin pathway | CD44CD166TGF- | ● | [24,40,41] |
CXCR4 | C-X-C chemokine receptor type 4 | ● | ● | ● | ND | ● | CXCR4/SDF-1pathway | CXCR4 | ● | [42] |
ABCB1/MDR1ABCG2 | ABC transporters | ● | ● | ● | ND | ● | JAK/STAT pathwayHH/PTCH1 pathway | ABCB1/MDR1ABCG2 | ● | [23,33,43-45] |
SP | Side population | ● | ● | ● | ND | ● | Wnt/β-catenin pathway | ND | ● | [21,23,44,46-48] |
Lrig1 | Regulatory factor of cell cycle | ● | ● | ● | ND | ● | ErbB pathway | Lrig1 | ● | [49] |
2-, 5-, 3- and 5- integrins | Cell adhesion molecule | ● | ● | ND | ND | ● | p38/ERK pathway | Integrins | ND | [23] |
Intracellular markers | Function | Physiological significance | Involved signaling pathways | Therapeutic targets | Prognostic marker of GC | Ref. | ||||
Tumorigenicity/GCSC generation | Spheroid formation | Chemo-resistance | Radio-resistance | EMT/metastasis | ||||||
DOCK6 | Dock-C subfamily guanine nucleotide exchanger | ● | ● | ● | ● | ● | Wnt/β-catenin pathway | DOCK6 | ● | [50] |
Mist1 | Transcriptional factor | ● | ● | ● | ND | ● | Wnt/β-catenin pathway | Mist1 | ● | [51] |
MSI-1 | RNA-binding protein | ● | ● | ● | ND | ● | EGFR pathway | MSI-1 | ● | [48] |
NANOG | Transcription factor | ● | ● | ● | ND | ● | Wnt/β-catenin pathwayJAK-STAT pathway | NANOG | ● | [23,52] |
Oct3/4 | Octamer-binding transcription factor 3/4 | ● | ● | ● | ND | ● | Wnt/β-catenin pathwayJAK-STAT pathway | Oct3/4 | ● | [23,53] |
SOX2 | Sex determining region Y-box 2 | ● | ● | ● | ND | ● | Wnt/β-catenin pathwayJAK-STAT pathway | SOX2MiR-134all-trans retinoic acid | ● | [52-57] |
GCSCs pathway | Involved pathway proteins | Therapeutic inhibitor or drug | Ref. |
Hedgehog (HH) | PTCH1, SMO, GLI | Vismodegib5E1RobotnikininGANT58GANT61HPI1-4GenisteinResveratrolCyclopamineMir-218SaridegibBMS-833923ErismodegibPF-0449913LY2940680 | [27,28,83,84] |
Notch/STAT3 | Notch ligands (DLL), Notch receptors, JAK, ERK, STAT3 | NapabucasinDemclzumab (anti-DLL4)TarextumabBBI-608 | [28,76,85,86] |
NANOG | NANOG, STAT3, Kinases | NapabucasinBBI-608BB1-503 | [28,73,75,85] |
Wnt/β-catenin | Wnt, β-catenin, LRP/FZD | Napabucasin BBI-608Vantictumab (anti-FZD)LGK974Foxy-5 | [28,77,78,85,86] |
- Citation: Hsieh HL, Yu MC, Cheng LC, Yeh TS, Tsai MM. Molecular mechanism of therapeutic approaches for human gastric cancer stem cells. World J Stem Cells 2022; 14(1): 76-91
- URL: https://www.wjgnet.com/1948-0210/full/v14/i1/76.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v14.i1.76